European Patent Office

T 1525/10 (Sustained release of fluvastatin/NOVARTIS AG) of 20.09.2011

European Case Law Identifier
ECLI:EP:BA:2011:T152510.20110920
Date of decision
20 September 2011
Case number
T 1525/10
Petition for review of
-
Application number
97944240.7
Language of proceedings
English
Distribution
Distributed to board chairmen (C)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
Pharmaceutical compositions for sustained release of the HMG-CoA reductase inhibitor fluvastatin
Applicant name
Novartis AG
Novartis Pharma GmbH
Opponent name
Ratiopharm GmbH
Actavis UK Ltd
Actavis GmbH
Mylan S.A.S.
Board
3.3.02
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 12(4)
Keywords
Main request and auxiliary request I - clarity (no): parameter and method for measuring it not clearly defined
Auxiliary request I - Article 123(2) EPC (no): unallowable generalisation
Auxiliary request II - admission (no): request withdrawn in first instance proceedings
Catchword
-

ORDER

For these reasons it is decided that:

The appeal is dismissed.